Loading
A phase 3 trial of Pamiparib capsule in ovarian cancer, run by BeiGene, active and no longer recruiting.
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer is a phase 3 interventional study registered as NCT03519230 by BeiGene, with 224 participants enrolled, started 2018-05-14 and due to reach its primary completion in 2025-12-01. Interventions recorded: Pamiparib capsule and Placebo capsule.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/